{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:10:30Z","timestamp":1789783830648,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.eplepsyres.2007.06.002","type":"journal-article","created":{"date-parts":[[2007,8,8]],"date-time":"2007-08-08T07:22:54Z","timestamp":1186557774000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The SKATE\u2122 study: An open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy"],"prefix":"10.1016","volume":"76","author":[{"given":"Bernhard J.","family":"Steinhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest R.","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Paesschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ryvlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Schelstraete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2007.06.002_bib1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1059-1311(02)00251-0","article-title":"Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy","volume":"12","author":"Ben-Menachem","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.09.005","article-title":"Efficacy and safety of levetiracetam 1000\u20133000mg\/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study","volume":"63","author":"Beran","year":"2005","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib4","doi-asserted-by":"crossref","unstructured":"Berkovic, S.F., Knowlton, R.C., Leroy, R.F., Schiemann, J., Falter, U., 2007. On behalf of the Levetiracetam NO1057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology [Epub ahead of print].","DOI":"10.1212\/01.wnl.0000268699.34614.d3"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1059-1311(02)00258-3","article-title":"Clinical experience of marketed levetiracetam in an epilepsy clinic\u2014a one year follow up study","volume":"12","author":"Betts","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/pgmj.2004.019976","article-title":"New drugs for the treatment of epilepsy: a practical approach","volume":"80","author":"Beyenburg","year":"2004","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","article-title":"Dose\u2013response effect of levetiracetam 1000 and 2000mg\/day in partial epilepsy","volume":"48","author":"Boon","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib11","doi-asserted-by":"crossref","unstructured":"Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981, 22, 489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1528-1157.1996.tb00612.x","article-title":"A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10","volume":"37","author":"Cramer","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2007.06.002_bib13","first-page":"199","article-title":"Patient-rated priorities and relationship to distress in health-related quality of life domains: the QOLIE-31-P and QOLIE-10-P in a long-term levetiracetam study","volume":"43","author":"Cramer","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib15","doi-asserted-by":"crossref","first-page":"15268","DOI":"10.1073\/pnas.96.26.15268","article-title":"Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)","volume":"96","author":"Crowder","year":"1999","journal-title":"PNAS"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jnnp.2005.064626","article-title":"The long term retention of levetiracetam in a large cohort of patients with epilepsy","volume":"77","author":"Depondt","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.yebeh.2003.09.007","article-title":"Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial","volume":"4","author":"Ferrendelli","year":"2003","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0404.2006.00647.x","article-title":"Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the SKATE trial","volume":"113","author":"Genton","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2005.01.005","article-title":"Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials","volume":"64","author":"Gidal","year":"2005","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib21","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"A double-blind randomized placebo-controlled trial of levetiracetam adjunctive therapy in children with partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib22","unstructured":"ICH E6 Note for Guidance on Good Clinical Practice (CPMP\/ICH\/135\/95), 1996. EMEA; July."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.seizure.2006.05.013","article-title":"Efficacy and safety of levetiracetam in clinical practice: results of the SKATE\u2122 trial from Belgium and The Netherlands","volume":"15","author":"Lambrechts","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-1211(01)00253-4","article-title":"Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"46","author":"Levy","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib26","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib27","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1468-1331.2006.01381.x","article-title":"Assessment of a dose\u2013response relationship of levetiracetam","volume":"13","author":"Meencke","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(03)00080-9","article-title":"The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study","volume":"54","author":"Morrell","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1528-1157.2002.57701.x","article-title":"Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women","volume":"43","author":"Ragueneau-Majlessi","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0920-1211(01)00293-5","article-title":"Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin","volume":"47","author":"Ragueneau-Majlessi","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.33588\/rn.3812.2004259","article-title":"Grupo Espa\u00f1ol del Estudio SKATE Seguridad del levetiracetam como tratamiento adyuvante en la epilepsia: el estudio SKATE en Espa\u00f1a","volume":"38","author":"Salas-Puig","year":"2004","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2007.06.002_bib34","first-page":"153","article-title":"Skate\u2122 trial interim analysis: confirmation of safety and efficacy of levetiracetam (KEPPRA\u00ae) as adjunctive therapy in patients with refractory epilepsy","volume":"44","author":"Steinhoff","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2007.06.002_bib35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.seizure.2005.08.005","article-title":"Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland","volume":"14","author":"Steinhoff","year":"2005","journal-title":"Seizure"},{"issue":"Suppl. 6","key":"10.1016\/j.eplepsyres.2007.06.002_bib36","first-page":"54","article-title":"Efficacy and safety of levetiracetam 3000mg\/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures","volume":"46","author":"Verdru","year":"2005","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121107001787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121107001787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:17:44Z","timestamp":1760275064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121107001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0920121107001787"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2007.06.002","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The SKATE\u2122 study: An open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2007.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}